008930.KS
Hanmi Science Co., Ltd. [008930.KS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
008930.KS Stock Summary
Top 008930.KS Correlated Resources
008930.KS
Top 10 Correlated ETFs
008930.KS
Top 10 Correlated Stocks
008930.KS
008930.KS Financial details
Company Rating
Buy
Market Cap
2105.64B
Income
50.74B
Revenue
1021.32B
Book val./share
11080.13
Cash/share
-
Dividend
200
Dividend %
0.64%
Employees
93
Optionable
No
Shortable
Yes
Earnings
25 Jan 2023
P/E
40.48
Forward P/E
-
PEG
3.25
P/S
2.01
P/B
2.82
P/C
-
P/FCF
213.59
Quick Ratio
-
Current Ratio
1.03
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
770.79
EPS next Y
-
EPS next Q
-
EPS this Y
89.78%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
6.81%
Revenue last 5Y
7.81%
Revenue Q/Q
-0.86%
EPS Q/Q
9.01%
-
-
-
-
SMA20
-6.06%
SMA50
-16.08%
SMA100
-22.65%
Inst Own
-
Inst Trans
-
ROA
5%
ROE
7%
ROC
0.07%
Gross Margin
78%
Oper. Margin
6%
Profit Margin
5%
Payout
26%
Shs Outstand
67.27M
Shs Float
19.63M
-
-
-
-
Target Price
-
52W Range
29050.0-58039.215
52W High
-46.24%
52W Low
+7.4%
RSI
41
Rel Volume
0.41
Avg Volume
118.79K
Volume
48.41K
Perf Week
0.97%
Perf Month
-0.79%
Perf Quarter
-25%
Perf Half Y
-32.54%
-
-
-
-
Beta
1.41879
-
-
Volatility
160.04%, 1328.12%
Prev Close
-0.32%
Price
31200
Change
-0.95%
008930.KS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 10.17K | 10.96K | 12.62K | 13K | 14.4K | |
| Net income per share | 468.58 | 278.92 | 475.26 | 342.61 | 650.96 | |
| Operating cash flow per share | -524.88 | 41.81 | 201.35 | 209.46 | 207.52 | |
| Free cash flow per share | -589.31 | 23.58 | 170.97 | 179.89 | 173.95 | |
| Cash per share | 683.27 | 415.72 | 264.54 | 227.79 | 252.09 | |
| Book value per share | 10.37K | 10.11K | 9.98K | 9.99K | 10.46K | |
| Tangible book value per share | 10.17K | 9.94K | 9.82K | 9.85K | 10.35K | |
| Share holders equity per share | 10.37K | 10.11K | 9.98K | 9.99K | 10.46K | |
| Interest debt per share | 408.66 | 326.57 | 728.99 | 805.33 | 883.59 | |
| Market cap | 6343.36B | 4401.57B | 2064.1B | 5212.71B | 2961.93B | |
| Enterprise value | 6330B | 4394.71B | 2092.77B | 5249.29B | 3001.84B | |
| P/E ratio | 210.96 | 244.27 | 67.14 | 230.64 | 68.98 | |
| Price to sales ratio | 9.72 | 6.22 | 2.53 | 6.08 | 3.12 | |
| POCF ratio | -188.33 | 1.63K | 158.48 | 377.25 | 216.36 | |
| PFCF ratio | -167.74 | 2.89K | 186.65 | 439.27 | 258.11 | |
| P/B Ratio | 9.54 | 6.74 | 3.2 | 7.91 | 4.29 | |
| PTB ratio | 9.54 | 6.74 | 3.2 | 7.91 | 4.29 | |
| EV to sales | 9.7 | 6.21 | 2.56 | 6.12 | 3.16 | |
| Enterprise value over EBITDA | 164.17 | 179.22 | 48.07 | 138.6 | 53.44 | |
| EV to operating cash flow | -187.94 | 1.63K | 160.69 | 379.9 | 219.28 | |
| EV to free cash flow | -167.39 | 2.89K | 189.24 | 442.36 | 261.59 | |
| Earnings yield | 0 | 0 | 0.01 | 0 | 0.01 | |
| Free cash flow yield | -0.01 | 0 | 0.01 | 0 | 0 | |
| Debt to equity | 0 | 0 | 0 | 0.01 | 0 | |
| Debt to assets | 0.29 | 0.29 | 0.29 | 0.29 | 0.27 | |
| Net debt to EBITDA | -0.35 | -0.28 | 0.66 | 0.97 | 0.71 | |
| Current ratio | 1.07 | 1.08 | 0.95 | 0.98 | 1.01 | |
| Interest coverage | 11.41 | 10.01 | 9.33 | 14.83 | 16.03 | |
| Income quality | -1.12 | 0.15 | 0.42 | 0.61 | 0.32 | |
| Dividend Yield | 0 | 0 | 0.01 | 0 | 0 | |
| Payout ratio | 0 | 0.68 | 0.4 | 0.56 | 0.3 | |
| Sales general and administrative to revenue | 0.88 | 0.02 | 0.01 | 0.01 | 0.01 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Capex to operating cash flow | 0.12 | -0.44 | -0.15 | -0.14 | -0.16 | |
| Capex to revenue | -0.01 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.88 | -0.26 | -0.31 | -0.31 | -0.42 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 10.45K | 7.96K | 10.33K | 8.77K | 12.38K | |
| ROIC | 0.02 | 0.02 | 0.02 | 0.04 | 0.04 | |
| Return on tangible assets | 0.03 | 0.02 | 0.03 | 0.02 | 0.05 | |
| Graham Net | -2.74K | -2.87K | -3.05K | -2.95K | -2.88K | |
| Working capital | 16.67B | 17.23B | -11.11B | -4.39B | 1.56B | |
| Tangible asset value | 652.6B | 641.91B | 635.28B | 649.92B | 682.71B | |
| Net current asset value | -12.37B | -18.99B | -48.07B | -48.76B | -37.04B | |
| Invested capital | 0.04 | 0.03 | 0.07 | 0.08 | 0.08 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 150.43B | 138.74B | 127.42B | 123.93B | 114.25B | |
| Average inventory | 108.95B | 106.5B | 105.53B | 110.19B | 108.08B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 91.04 | 67.46 | 61.41 | 46.69 | |
| Days of inventory on hand | 0 | 60.96 | 51.99 | 54.59 | 47.32 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 4.01 | 5.41 | 5.94 | 7.82 | |
| Inventory turnover | 0 | 5.99 | 7.02 | 6.69 | 7.71 | |
| ROE | 0.05 | 0.03 | 0.05 | 0.03 | 0.06 | |
| Capex per share | -64.44 | -18.24 | -30.38 | -29.57 | -33.57 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
| Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 3.59K | 4K | 3.83K | 3.86K | 3.83K | |
| Net income per share | 245 | 67.19 | 257.81 | 213.29 | 232.51 | |
| Operating cash flow per share | 45.9 | 51.3 | -19.25 | 152.45 | 48.42 | |
| Free cash flow per share | 30.59 | 43.95 | -28.33 | 120.06 | 10.4 | |
| Cash per share | 253.3 | 252.62 | 0 | 0 | 0 | |
| Book value per share | 10.48K | 10.49K | 10.57K | 10.79K | 11.08K | |
| Tangible book value per share | 10.36K | 10.37K | 10.57K | 10.79K | 11.08K | |
| Share holders equity per share | 10.48K | 10.49K | 10.57K | 10.79K | 11.08K | |
| Interest debt per share | 908.96 | 865.38 | -7.87 | -9.42 | -9.56 | |
| Market cap | 4007.86B | 3567.96B | 2939.29B | 2636.47B | 2076.92B | |
| Enterprise value | 4050.6B | 3607.87B | 2939.29B | 2636.47B | 2076.92B | |
| P/E ratio | 62.12 | 201.68 | 43.3 | 46.94 | 33.92 | |
| Price to sales ratio | 16.95 | 13.55 | 11.67 | 10.38 | 8.25 | |
| POCF ratio | 1.33K | 1.06K | -2.32K | 262.71 | 651.62 | |
| PFCF ratio | 1.99K | 1.23K | -1.58K | 333.58 | 3.03K | |
| P/B Ratio | 5.81 | 5.17 | 4.22 | 3.71 | 2.85 | |
| PTB ratio | 5.81 | 5.17 | 4.22 | 3.71 | 2.85 | |
| EV to sales | 17.13 | 13.7 | 11.67 | 10.38 | 8.25 | |
| Enterprise value over EBITDA | 209.62 | 525.01 | 149.46 | 177.44 | 132.07 | |
| EV to operating cash flow | 1.34K | 1.07K | -2.32K | 262.71 | 651.62 | |
| EV to free cash flow | 2.01K | 1.25K | -1.58K | 333.58 | 3.03K | |
| Earnings yield | 0 | 0 | 0.01 | 0.01 | 0.01 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0.27 | 0.27 | 0.27 | 0.24 | 0.24 | |
| Net debt to EBITDA | 2.21 | 5.81 | 0 | 0 | 0 | |
| Current ratio | 1 | 1.01 | 1 | 1.03 | 1.03 | |
| Interest coverage | 16.34 | 11.24 | -37.94 | -25.5 | -26.72 | |
| Income quality | 0.19 | 0.76 | -0.07 | 0.71 | 0.21 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.01 | 0.01 | 0.97 | 0.97 | 0.98 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.01 | 0.01 | 0 | 0 | 0 | |
| Capex to operating cash flow | -0.33 | -0.14 | 0.47 | -0.21 | -0.79 | |
| Capex to revenue | 0 | 0 | 0 | -0.01 | -0.01 | |
| Capex to depreciation | -0.78 | -0.37 | -0.52 | -1.84 | -2.16 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 7.6K | 3.98K | 7.83K | 7.19K | 7.61K | |
| ROIC | 0.01 | 0.01 | 0.03 | 0.02 | 0.02 | |
| Return on tangible assets | 0.02 | 0 | 0.02 | 0.01 | 0.02 | |
| Graham Net | -2.82K | -2.89K | -3.95K | -3.47K | -3.56K | |
| Working capital | 431.33M | 1.56B | -673.7M | 5.46B | 6.45B | |
| Tangible asset value | 682.01B | 682.71B | 0 | 0 | 0 | |
| Net current asset value | -41.36B | -37.04B | -40.3B | -36.54B | -35.91B | |
| Invested capital | 0.09 | 0.08 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 46.5 | 41.18 | 0 | 0 | 0 | |
| Days of inventory on hand | 47.74 | 41.73 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 1.94 | 2.19 | 0 | 0 | 0 | |
| Inventory turnover | 1.89 | 2.16 | 0 | 0 | 0 | |
| ROE | 0.02 | 0.01 | 0.02 | 0.02 | 0.02 | |
| Capex per share | -15.31 | -7.36 | -9.08 | -32.39 | -38.02 |
008930.KS Frequently Asked Questions
What is Hanmi Science Co., Ltd. stock symbol ?
Hanmi Science Co., Ltd. is a US stock and trading under the symbol 008930.KS
What is Hanmi Science Co., Ltd. stock quote today ?
Hanmi Science Co., Ltd. stock price is $31200 today.
Is Hanmi Science Co., Ltd. stock public?
Yes, Hanmi Science Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 118.79K
- Market Capitalization 2105.64B
- Employee 93
- Headquarters Seoul,US
- IPO Date 2005-09-29
-
Website
https://www.hanmiscience.co.kr 
Hanmi Science Co., Ltd., through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally. It develops drugs in the areas of diabetes and anti-cancer. The company also offers drug substances, general medicines, health functional foods, and nutrition and health products and services. In addition, it operates an online pharmacy; and offers pharmaceutical management automation systems. The company was formerly known as Hanmi Holdings Co., Ltd. and changed its name to Hanmi Science Co., Ltd. in March 2012. Hanmi Science Co., Ltd. was founded in 1973 and is based in Seoul, South Korea.
